Chargement en cours...
How can we improve antibody-based cancer therapy?
Monoclonal antibodies (mAbs) as a class of novel oncology therapeutics are demonstrating clinical efficacy as measured by tumor response (shrinkage in tumor size), and prolongations in progression-free survival (PFS) and overall survival (OS). However, clinical benefits are often limited to when ant...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Landes Bioscience
2009
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2715179/ https://ncbi.nlm.nih.gov/pubmed/20046576 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|